###### Strengths and limitations of this study

-   Use of national aggregate data gives a comprehensive picture of the country.

-   The ecological design of the study may result in 'ecological fallacy'.

-   Despite use of aggregate data, findings are similar to studies using individual data.

-   Use of tuberculosis (TB) case notifications does not account for undiagnosed TB cases.

-   All factors contributing to declining TB case notifications are not accounted for.

Background {#s1}
==========

Tuberculosis (TB), one of the oldest bacterial infections known to mankind and the HIV infection are a deadly combination. While the lifetime risk of developing active TB disease among people with latent TB infection (LTBI) is 5%--15%,[@R1] those with HIV have a 5%--15% annual risk of acquiring active TB disease.[@R2] The TB epidemic in sub-Saharan Africa is largely driven by the HIV epidemic which disproportionately affects this region. About 70% of the 36.9 million people living with HIV (PLHIV) globally live in sub-Saharan Africa, of whom 76% are found in the eastern and southern regions. This is despite the fact that sub-Saharan Africa contributes only 14% of the world's population.[@R3]

Of the estimated 10 million people who developed TB disease in 2017, 9% were PLHIV of whom 72% lived in the Africa region.[@R4] Among those with TB and HIV coinfection, the majority (84%) were from the Africa region.[@R4] Despite this large prevalence, there has been a 44% decline in the number of HIV/TB associated deaths since 2000. This is largely attributed to an increased uptake of antiretroviral therapy (ART) among those with HIV-associated TB. Coverage of ART in Africa has more than doubled from 35% in 2005 to 84% in 2017.[@R4]

ART is associated with a 67% reduced risk of developing active TB disease among PLHIV[@R6] and an even further reduction in recurrent TB.[@R7] ART has also been shown to reduce the population incidence of TB by between 27% and 80%.[@R8] However, despite ART having a TB protective effect at the individual level, which has further been shown to positively correlate with higher updated CD4 cell counts,[@R10] the incidence of TB still remains higher in the HIV-positive population compared with the HIV-negative population.[@R11]

To further mitigate TB in this high-risk group, isoniazid preventive therapy (IPT) has also been found to be effective in reducing the incidence of TB and death from TB among PLHIV with further reductions in TB risk of up to 90% among those receiving both IPT and ART.[@R12] This has led the WHO to recommend initiation of IPT among PLHIV enrolled in ART care in whom TB has been excluded using a clinical TB screening algorithm.[@R15]

Zimbabwe is one of the sub-Saharan African countries with a largely HIV-driven TB epidemic and is among the 14 countries globally with a triple burden of TB, TB/HIV and multidrug resistant TB.[@R4] A previous publication from Zimbabwe evaluating a 14-year period from 2000 to 2013 showed that with increasing ART coverage since its inception in the public sector in 2004, annual TB case notification rates more than halved for all forms of TB. Furthermore, the largest declines were among those with recurrent TB (53%), new smear-negative pulmonary TB (58%) and extrapulmonary TB (58%).[@R16] Zimbabwe also adopted WHO guidance on provision of IPT among PLHIV in 2011. There was an initial pilot phase in 10 health facilities where the delivery of IPT was found to be feasible, and this was followed by nationwide roll-out to most of the public health facilities in the country.[@R17] The country has also adopted the 'HIV treat all' approach from mid-2016 where those who test HIV positive are immediately eligible for ART initiation regardless of their CD4 cell count or WHO clinical staging.

We hypothesise that the nationwide scale-up of IPT; the continued increase in ART coverage and the earlier initiation of ART have all had a population impact on reducing TB incidence in Zimbabwe, translating to further declines in TB case notification rates. Currently, there are no reports or published papers comparing the national scale-up of IPT and ART with national TB case notification rates. We therefore describe in this paper the association between IPT and ART scale-up and annual TB case notification rates in Zimbabwe from 2000 to 2018.

Methods {#s2}
=======

Study design {#s2-1}
------------

This was an ecological study design using aggregate programme data to analyse for trends and associations.

Setting {#s2-2}
-------

Zimbabwe is a developing country in Southern African with a population of 13 million[@R19] according to latest census data. There is a gross national index per capita of US\$860[@R20] and 72.3% of the population live below the national poverty line.[@R20] The country has a high HIV prevalence rate of 15%, and the total number of adults and children living with HIV was estimated at 1.3 million in 2018 according to the Joint United Nations Programme on HIV/AIDS (UNAIDS).[@R21]

### The National Art Programme in Zimbabwe {#s2-2-1}

Antiretroviral drugs were first offered in public health facilities in 2004 under the National ART Programme at five central level hospitals. As of December 2018, ART was available at 1604 (93%) out of 1722 health facilities nationwide.[@R22] Since the inception of the ART programme in 2004, the criteria for initiating ART among adults has shifted from a CD4 cell count threshold of \<200 cells/mL until 2010, to \<350 cells/mL from 2011 to 2013 and to \<500 cells/mL from 2014 in accordance with WHO guidelines.[@R23] Those with advanced HIV disease have always been eligible for ART regardless of CD4 cell count.

Towards the end of 2013, there was a shift towards universal eligibility for lifelong ART in Zimbabwe. This started under option B+ when all HIV-infected pregnant and breastfeeding women were initiated on ART irrespective of their CD4 counts or WHO staging. Over this same period, ART regimens became simpler, less toxic and with a reduced pill burden given the transition to one pill per day fixed-dose combination regimens. From mid-2016 onwards, the country started implementing the 'HIV treat all' approach whereby all patients who were diagnosed HIV positive are immediately eligible for ART initiation regardless of CD4 cell count or WHO clinical staging.

### Intensive TB case finding, IPT initiation and enrolment in art care {#s2-2-2}

All confirmed PLHIV in Zimbabwe are enrolled at ART clinics to receive HIV treatment and care services. According to Zimbabwe's national IPT guidelines, all PLHIV should be screened for active TB at every clinic visit or every encounter with a health worker using the WHO recommended four-symptom TB screening checklist.[@R26] If PLHIV present with any of the four symptoms (cough of any duration, night sweats, weight loss and fever), they are considered as presumptive TB cases and have their sputum specimens collected for investigation by smear microscopy or Xpert MTB/Rif assay (Cepheid, Sunnyvale, California, USA). Those who are negative on smear microscopy or Xpert MTB/Rif assay or both and who have no other symptoms or signs of extrapulmonary or smear-negative PTB, including chest radiography if necessary, are not diagnosed with active TB and are potentially eligible for IPT.

IPT eligibility has changed over time. At the start of the programme in 2011, all patients enrolled in HIV care were eligible for IPT regardless of ART status, provided active TB was excluded. Since the national ART programme moved towards an 'HIV treat all' approach, all PLHIV in pre-ART care were recalled to health facilities for ART initiation and were prioritised for ART care first and then initiated on IPT. All those eligible for IPT are started on a 6-month daily oral dose of isoniazid (5 mg/kg body weight for adults or 10 mg/kg body weight for children) plus a daily low dose of pyridoxine (25 mg/day). To prevent unnecessary visits to health facilities, resupplies of IPT and pyridoxine are synchronised to ARV resupplies until completion of TB preventive treatment. During clinic visits, patients are assessed through self-reporting and pill counts for adherence, and they are also screened for TB. Patients found to have developed active TB disease are discontinued from IPT and are subsequently treated for TB according to national TB guidelines.[@R26] By the end of June 2019, there were 1280 (74%) out of 1722 public health facilities offering IPT in addition to ART across the country's 10 provinces (National ART Programme data).

### The National TB Programme in Zimbabwe {#s2-2-3}

Zimbabwe like other countries with a high prevalence of TB has a well-established WHO recommended directly observed treatment short course (DOTS)[@R27] national TB programme (NTP), whereby TB treatment services are integrated with general health services at all health facilities countrywide. This DOTS model consists of a centralised and prioritised system of TB monitoring, recording and training of TB case management, and there is also a standardised recording and reporting system that allows assessment of treatment results. National TB treatment outcomes are recorded and reported in line with WHO guidelines and are classified as treatment success (cured plus treatment completed), loss to follow-up (LTFU), died, transferred out or not evaluated and failed treatment.

Patients with TB are classified as either new or previously treated TB cases, whereby new cases are those who have never received anti-TB treatment or have previously received anti-TB drugs for \<30 days, while previously treated TB cases are those patients who have previously received anti-TB drugs for \>1 month. Prior to 2013, new TB cases were divided into smear-positive pulmonary (PTB), smear-negative PTB or extrapulmonary TB (EPTB) cases, while retreatment patients with TB were categorised as follows: (1) relapse cases, (2) treatment after failure, (3) treatment after LTFU or (4) 'retreatment other' based on smear microscopy. However from 2013 onwards, both new and recurrent TB cases have been classified as new/recurrent bacteriologically confirmed, clinically diagnosed and EPTB cases based on Xpert MTB/Rif results, the preferred first-line TB diagnostic test. The NTP also ensures these drug-susceptible patients with TB are prescribed a standardised treatment regimen of 6 months for new TB cases or 8 months for recurrent TB cases: doses are observed by a healthcare worker or community health worker for at least the first 2 months of therapy.

Study population {#s2-3}
----------------

The study population included: all PLHIV reported nationally in ART care at the end of each year; all PLHIV in ART care who were initiated on IPT annually and all patients annually diagnosed and notified with TB in Zimbabwe between 2000 and 2018.

Patient and public involvement {#s2-4}
------------------------------

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination of our research study.

Data variables and sources of data {#s2-5}
----------------------------------

National aggregate data on annual estimated numbers of PLHIV and annual numbers receiving ART were obtained from UNAIDS and WHO.[@R21] Data on PLHIV estimates are generated annually using the Estimation and Projection Package and Spectrum software[@R29] from UNAIDS based on primary collected data from census reports, antenatal clinic surveillance, population-based surveys and programme data. National population figures were obtained from the 2002 and 2012 national census reports with intercensus projections for the periods in between these reports and after 2012.[@R19] Data on annual numbers started on IPT were obtained from the Zimbabwe Demographic Health Information System version 2 (DHIS2). Finally, aggregate data on numbers notified each year with TB and further stratified by type and category of TB were obtained from the WHO website.[@R32]

Analysis and statistics {#s2-6}
-----------------------

Data were analysed by plotting bar and line graphs of the various indicators over time from 2000 to 2018. ART coverage was calculated by dividing the annual total number of PLHIV receiving ART by the annual estimated number of PLHIV, instead of relying on ART coverages reported in annual UNAIDS or WHO reports since these were dependent on changing ART eligibility criteria over the years. IPT coverage rates were calculated as cumulative annual numbers of PLHIV in ART care ever started on IPT divided by annual numbers of PLHIV receiving ART.

Annual TB case notification rates were calculated by dividing annual TB case notifications by annual national population figures to obtain case notifications per 100 000 population. Changes in TB notification rates between 2000 and 2018 were determined by comparing the highest TB case notification rates prior to national ART scale-up and the lowest annual TB case notification rates after roll-out of both ART (in 2004) and IPT (in 2012) using tests for proportions in Stata V.15.0 (StataCorp, College Station, Texas, USA). Levels of significance were set at 5%.

Results {#s3}
=======

Since the inception of ART in the public sector in 2004, there was a substantial increase in the number and proportion of PLHIV initiated on ART from 8400 (\<1% ART coverage) in 2004 to over 1 million (88% ART coverage) by the end of 2018 ([figure 1](#F1){ref-type="fig"}). The number and proportion of PLHIV in ART care who were ever started on IPT increased from 98 (\<1% coverage) in 2012 to approximately 373 917 (33% coverage) by the end of 2018 ([figure 2](#F2){ref-type="fig"}).

![Numbers and coverage of PLHIV alive on ART in Zimbabwe, 2000--2018. ART coverage was calculated using the estimated HIV-infected population as the denominator from national projections obtained from the Joint United Nations Programme on HIV/AIDS Estimation and Projection Package and Spectrum software). ART, antiretroviral therapy; PLHIV, people living with the HIV.](bmjopen-2019-034721f01){#F1}

![Numbers on IPT and IPT coverage among PLHIV receiving ART in Zimbabwe, 2000--2018. IPT coverage was calculated using the cumulative annual numbers started on IPT as the numerator and cumulative annual numbers alive on ART as reported from the Zimbabwe DHIS2 reporting database. ART, antiretroviral therapy; DHIS, Demographic Health Information System; IPT, isoniazid preventive therapy; PLHIV, people living with the HIV.](bmjopen-2019-034721f02){#F2}

All TB case notification rates increased between 2000 and 2004 from a high of 446 cases/100 000 population to a peak of 509 cases/100 000 population before declining steeply to 315 cases/100 000 population in 2008 ([figure 3](#F3){ref-type="fig"}). Following this, there was a brief increase in case notification rates to 372 cases/100 000 population before a steady decline to an all-time low of 173 cases/100 000 population in 2018. A similar trend was observed for new TB cases which constituted the majority of all TB case notifications. Retreatment TB cases increased fourfold between 2001 and 2004 from 13 cases/100 000 population to 58 cases/100 000 population before declining to 20 cases/100 000 population in 2007. Thereafter, case notification rates increased to a plateau of 37 cases/100 000 population in 2009 and 2010 prior to eventually declining steadily over time to 11 cases/100 000 population by the end of 2018.

![Notification rates of all TB cases in Zimbabwe stratified by TB category, 2000--2018. PTB, pulmonary TB; TB, tuberculosis.](bmjopen-2019-034721f03){#F3}

Clinically diagnosed PTB cases increased from 242 cases/100 000 population in 2000 to an all-time peak of 284 cases/100 000 population in 2002 and significantly declined although with intermittent increases observed in 2004 and 2009--2010 before reaching an all-time low of 63 cases/100 000 population in 2017 ([figure 4](#F4){ref-type="fig"}). Bacteriologically confirmed PTB cases also increased from 126 cases/100 000 population in 2000 to an all-time peak of 137 cases/100 000 population in 2002 and later declined steadily to 79 cases/100 000 population in 2008. Thereafter the rate of cases increased slightly before declining to an all-time low of 77 cases/100 000 population in 2018. Extrapulmonary TB case notification rates declined steadily over time from 78 cases/100 000 population in 2000 to their lowest of 16 cases/100 000 population in 2018, with slight increases observed during 2001--2002 and 2008--2009.

![Notification rates of new TB cases in Zimbabwe stratified by type of TB, 2000--2018. PTB, pulmonary tuberculosis; TB, tuberculosis.](bmjopen-2019-034721f04){#F4}

In [figure 5](#F5){ref-type="fig"}, there was an observed decline in TB case notifications over the years with increasing ART and IPT coverage since their national roll-out in 2004 and 2012, respectively. In [table 1](#T1){ref-type="table"}, there were overall significant declines in all TB case notification rates between the highest recorded case notification rate prior to ART and IPT national roll-out in comparison with the lowest case notification rates after ART and IPT scale-up (66.1%, p\<0.001). Similar significant declines in case notification rates were observed among those with new TB (68.3%, p\<0.001) and among those with new clinically diagnosed PTB (77.8%, p\<0.001).

![Trends in notification rates of all TB cases versus ART and IPT coverage in Zimbabwe, 2000--2018. (ART coverage was calculated using the estimated HIV-infected population as the denominator from national projections obtained from the UNAIDS Estimation and Projection Package and Spectrum software. IPT coverage was calculated using the cumulative annual numbers started on IPT as the numerator and cumulative annual numbers alive on ART as reported from the Zimbabwe DHIS2 reporting database. ART, antiretroviral therapy; DHIS, Demographic Health Information System; TB, tuberculosis; UNAIDS, United nations Programme for HIV/AIDS.](bmjopen-2019-034721f05){#F5}

###### 

Comparisons of TB case notification rates, stratified by type and category prior to 2004 (at start of ART scale-up) and after ART roll-out and IPT roll-out (2012) in Zimbabwe

  Type of TB                         Highest notification rate (per 100 000)   Year   Lowest notification rate (per 100 000)   Year   Decrease (%) between highest and lowest   P value\*
  ---------------------------------- ----------------------------------------- ------ ---------------------------------------- ------ ----------------------------------------- -----------
  All TB                             510                                       2002   173                                      2018   66.1                                      \<0.001
  New TB                             501                                       2002   159                                      2018   68.3                                      \<0.001
   Bacteriologically confirmed PTB   137                                       2002   77                                       2018   43.8                                      0.143
   Clinically diagnosed PTB          284                                       2002   63                                       2017   77.8                                      \<0.001
   Extrapulmonary TB                 79                                        2002   16                                       2018   79.7                                      0.281
  Previously treated TB              58                                        2004   11                                       2018   81.0                                      0.432

\*Test of proportions comparing percentage decreases between the highest recorded case notification rate prior to ART and IPT scale-up and the lowest recorded case notification rate after ART roll-out (in 2004) and IPT roll-out (in 2012).

ART, antiretroviral therapy; EPTB, extrapulmonary TB; IPT, isoniazid preventive therapy; PTB, pulmonary tuberculosis; TB, tuberculosis.

Discussion {#s4}
==========

This study is a follow-on of a previous study showing the association between declines in TB case notifications from 2000 to 2013 and scale-up of ART in the public sector since its inception in 2004.[@R16] In this current study, we assessed TB case notification rates for a further 5-year period up to 2018 after ART coverage had nearly doubled from nearly half of all estimated PLHIV to nearly 9 in 10 PLHIV and after the National AIDS Programme had attained an IPT coverage of approximately one-third of patients receiving life-saving ART.

Our findings showed that these HIV-related interventions (ART and IPT) were associated with significant declines in TB case notification rates between the highest and lowest reported case notification rates prior to and after the inception of ART and IPT in the public sector, respectively. These declines were observed for all TB cases combined and among those with new TB, in particular those with new clinically diagnosed PTB. In comparison to the previous study,[@R16] there was a further percentage decline of TB case notification rates between the lowest recorded TB case notification rates reported then and those currently presented of 34%, 33%, 27%, 52% and 59% for all forms of TB, new TB, new clinically diagnosed PTB, new EPTB and previously-treated TB cases, respectively.

These findings reaffirm the population impact of the pooled TB-protective effect of ART and IPT in a setting where TB is mainly HIV driven. This may also be coupled with implementation of intensified TB case finding among PLHIV to identify those eligible for IPT. Simultaneously, those needing TB treatment can be identified and treated, thus resulting in improved infection control in ART care settings where newly diagnosed TB cases are most prevalent.[@R33]

The further national gains in significantly increasing ART coverage towards the UNAIDS 90% ART coverage target by adopting an 'HIV treat all' approach in recent years have resulted in 64% of all estimated PLHIV in Zimbabwe being virally suppressed according to the last 2015--2016 Zimbabwe Population HIV Impact Assessment population-based survey.[@R35] This has had a significant impact on the near threefold reduction in the estimated TB incidence in the population from 584 to 221 cases/100 000 population between 2000 and 2017.[@R4] In line with our findings, a modelling exercise involving countries from sub-Saharan Africa also showed that the most notable decline in incidence of HIV-associated TB is seen when those diagnosed HIV positive are immediately initiated on ART compared with delaying ART until 5 years after HIV seroconversion.[@R37]

Interestingly, the decline in TB case notifications which was higher in those with clinically diagnosed PTB has been sustained even though TB diagnosis has shifted from smear microscopy to Xpert MTB/Rif. The Xpert MTB/Rif assay is more sensitive in diagnosing TB in patients whose sputum smears are negative for acid-fast bacilli (which is more common among PLHIV),[@R38] and hence one might have anticipated an increase in numbers of TB cases detected rather than the observed decrease.

A recent modelling study showed that treatment of latent TB infection can result in a 14-fold decline in global TB incidence between 2013 and 2050 in comparison to no treatment of latent TB infection.[@R39] Therefore, despite the observed and encouraging decline in TB case notifications, there are still opportunities for further declines given that IPT coverage is only approximately one-third of PLHIV on ART. Uptake of IPT has slowed down because of resistance of some health workers who fear the development of isoniazid resistance coupled with fears among patients given a few anecdotal reports of serious side effects among some patients taking this prophylactic treatment. Although IPT completion rates in Zimbabwe are higher than reported elsewhere, completion rates are still suboptimal probably due to the increased pill burden of IPT over a 6--9 month duration.[@R17] Improved completion rates may lead to a further decline in TB case notification rates.

Zimbabwe's planned national roll-out of a shorter regimen of TB preventive therapy (namely, a 12-week course of weekly rifapentine plus isoniazid---3HP) for children and adult PLHIV, following the feasibility phase roll-out in 10 pilot sites beginning in early 2020, can potentially lead to increased TB preventive therapy coverage. This may lead to further declines in TB incidence among PLHIV in ART care. In comparison to the standard 6--9 months isoniazid monotherapy course, the 3HP prophylactic treatment course has been shown to have higher completion rates and a lower risk of adverse events, particularly hepatotoxicity.[@R40]

The major strength of this study is that national aggregate data that is routinely tracked as part of HIV/TB global response indicators were used, hence giving a comprehensive picture of what is prevailing in the country over time. The major limitation comes from the ecological design of the study which results in 'the ecological fallacy', whereby other factors that are attributed to the observed decline in TB case notifications over time aside from ART and IPT are not accounted for.[@R41] However, our findings are largely reliable as they are coherent with findings from well-conducted studies at the individual level using robust study methodologies.[@R12] There are other limitations. TB case notifications may underestimate the true TB cases in Zimbabwe over time especially among PLHIV. Despite the use of GeneXpert, the test has been shown to have low sensitivity and specificity in settings were HIV prevalence is \>30%.[@R38] There may also have been missed TB cases through suboptimal TB screening among patients attending health facilities and leakages along the care cascade to sputum collection, submission for laboratory diagnosis, return of results and commencement of TB treatment.[@R42] Nevertheless, based on TB treatment coverages for Zimbabwe that were reported by WHO, these were relatively constant around 70%,[@R32] hence the observed annual TB case notification rates are probably standardised for undiagnosed TB cases.

In conclusion, this study shows continued declining trends of TB case notification rates that support the continued scale-up of ART and TB preventive therapy among PLHIV as key strategies for mitigating the dual burden of HIV/AIDS and TB in Zimbabwe and other regions with HIV-driven TB epidemics.
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